Skip to content

Clinical Trial of the Sequence of Cardiovascular Genetic Counseling and Testing

Randomized Clinical Trial of the Sequence of Genetic Counseling and Testing to Optimize Efficiency, Patient Empowerment and Engagement, and Medical Adherence for Diverse Genetic Testing Indications

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05422573
Acronym
RESEQUENCEGC
Enrollment
393
Registered
2022-06-16
Start date
2022-12-20
Completion date
2026-06-30
Last updated
2026-09-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Genetic Counseling, Inherited Cardiac Disease

Keywords

inherited heart disease

Brief summary

Although pre-test genetic counseling is widely recommended and has come to dominate genetic counseling practice, tailored results-focused genetic counseling could both increase genetic counseling efficiency and improve genetic counseling outcomes for the growing number of patients seeking genetic testing for recommended genome-guided medical management. This study will test that hypothesis in adults referred for cardiovascular genetic counseling and testing at the Johns Hopkins Center for Inherited Heart Diseases. This study is a three-arm randomized clinical trial to evaluate two complementary approaches to shifting the primary genetic counseling session to post-test for 510 adults with two broad cardiovascular genetic counseling indications: diagnostic panel testing and family-specific variant testing. The investigators will compare usual care (pre-test genetic counseling appointment, results returned by phone / electronic health record) with online video-based pre-test tailored genetic education with an optional (efficiency arm) or required (flipped arm) phone call with a genetic counselor followed by a post-test genetic counseling appointment. The investigators hypothesize that post-test genetic counseling will: 1) increase efficiency, 2) promote patient empowerment and adherence, and 3) have similar genetic test-associated psychosocial impact.

Detailed description

This is a three-arm randomized clinical trial with a parallel-group design comparing usual care (pre-test genetic counseling, test results by phone/electronic health record (EHR)) to two approaches to post-test results-focused genetic counseling involving a pre-test educational video with an optional \[efficiency arm\] or required \[flipped arm\] phone call with a genetic counselor followed by a post-test genetic counseling appointment. Consented participants will be randomly allocated to the three study arms stratified by genetic testing indication (cardiovascular panel, family-specific variant). Questionnaires will be administered at 4 timepoints: 2 weeks before pre-test education/counseling (Q1), immediately after pre-test education/counseling and test ordered or declined (Q2), 2-weeks post-disclosure (Q3), and 6-months post-disclosure (Q4) (Aims 1-3). Data will be extracted from each participant's electronic health record (EHR) to record potential clinical covariates (Aims 1-3), validate self-reported adherence to medical recommendations (Aim 3), and obtain metrics to measure genetic counseling efficiency (Aim 4).

Interventions

BEHAVIORALpost-test cardiovascular genetic counseling with pre-test education by video

post-test cardiovascular genetic counseling with pre-test education by video

BEHAVIORALrequired phone call with genetic counselor pre-test

REQUIRED phone call with genetic counselor pre-test.

BEHAVIORALoptional phone call with genetic counselor pre-test

OPTIONAL phone call with genetic counselor pre-test

Sponsors

Johns Hopkins University
Lead SponsorOTHER
National Human Genome Research Institute (NHGRI)
CollaboratorNIH

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Cardiovascular panel testing inclusion criteria: 1. Adult (age 18+) scheduled for outpatient genetic counseling in the Johns Hopkins Center for Inherited Heart Diseases, 2. Clinical diagnosis or suspected clinical diagnosis of a potentially inherited cardiovascular disease including a) hypertrophic, dilated, or arrhythmogenic cardiomyopathy, b) ventricular or atrial arrhythmias or an ECG-pattern suspicious for an inherited cardiovascular disease including catecholaminergic polymorphic ventricular tachycardia, long QT syndrome, or Brugada syndrome, or c) a diagnosed or suspected lipid disorder or early-onset coronary artery disease, 3. next-generation cardiovascular sequencing panel clinically indicated. Family specific variant testing inclusion criteria: 1. Adult (age 18+) scheduled for outpatient genetic counseling in the Johns Hopkins Center for Inherited Heart Diseases, 2. Documented pathogenic or likely pathogenic variant in a gene associated with a hereditary cardiomyopathy, arrhythmia syndrome, or lipid disease in a family member, 3. Referred to the Center for Inherited Heart Diseases for family-specific variant testing.

Exclusion criteria

1. Previous genetic counseling at Johns Hopkins for this clinical indication, 2. Previous genetic testing that definitively identified the genetic cause of the patient's condition, 3. Patient unable to speak or read English, 4. Genetic counseling appointment is not anticipated to include genetic testing (for instance if it was scheduled to discuss family communication or adaptation to a new diagnosis), 5. Next generation sequencing panel not clinically indicated (panel cohort only).

Design outcomes

Primary

MeasureTime frameDescription
Change in empowerment as measured on the Genetic Counseling Outcomes Scale (GCOS)Baseline up to 2-weeks after genetic counseling result appointment / disclosureChange in empowerment as measured on the Genetic Counseling Outcomes Scale (GCOS). The GCOS is 24-item Likert scale with a 7-item response set. Scores range from 24-168 with higher scores indicating higher empowerment.
Anxiety as measured on the Hospital Anxiety and Depression Scale (HADS)6-months post results disclosureAnxiety as measured on the Hospital Anxiety and Depression Scale (HADS). The HADS contains 14 items measured on a 4-point Likert scale. The anxiety subscale contains 7 items. HADS subscale scores ≥8 indicate potentially clinically significant anxiety and depression and scores ≥10 a likely case.
Medical adherence as assessed by proportion of completed screening tests6-months post results disclosureProportion of recommended cardiology appointments and screening tests completed or scheduled
Efficiency as assessed by minutes of direct counseling timeUp to 6-months post results disclosureTotal minutes of counseling time per patient documented in the electronic health record including visit and phone notes.

Secondary

MeasureTime frameDescription
Change in engagement as assessed by Patient Activation MeasureBaseline, 6-months post results disclosureChange in patient engagement as measured by the short form of the Patient Activation Measure (PAM-13). The PAM-13 includes a 4-item Likert scale response set with higher scores indicating higher patient activation. To calculate the total PAM score, the raw score is divided by the number of items answered (excepting non-applicable items) and multiplied by 13. Then, this score is transformed to a scale with a theoretical range 0-100, based on calibration tables, with higher PAM scores indicating higher patient activation.
Informed Choice as assessed by Multidimensional Model of informed Choice pilot scalesup to 14 days post-educationMultidimensional Model of informed Choice pilot scales for familial hypercholesterolemia (FH) and cardiomyopathy/arrhythmia testing will be used. This is a scale that combines a subscale with 8 True/false knowledge about cardiovascular genetics and genetic testing questions scored as number correct with a 5-item scale with a Likert scale response set assessing attitudes toward genetic testing. The entire scale is scored by combining knowledge, values and testing choice made.

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORCynthia James

Johns Hopkins University

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Sep 10, 2026